Research Use Only Disclaimer
GLP-1 (S) / Cagri Blend is sold strictly for laboratory, academic and institutional research. It is not for human or animal consumption, injection, or any therapeutic, diagnostic or veterinary use. PCH Peptides does not provide dosage, administration or usage guidance.
What Is the GLP-1 (S) / Cagri Blend?
GLP-1 (S) / Cagri Blend is a two-component peptide formulation containing Semaglutide and Cagrilintide in equal amounts by weight.
Semaglutide is a lipidated analogue of glucagon-like peptide-1 (GLP-1) that interacts with the GLP-1 receptor. Cagrilintide is a long-acting, acylated amylin analogue investigated for its interactions with amylin receptor complexes and related calcitonin-family receptor systems.
Because these compounds interact with different receptor pathways, researchers investigate their molecular characteristics and signalling mechanisms in comparative biochemical and receptor-binding studies.
The blend provides 5mg of each compound, giving laboratories a predefined 1:1 ratio by weight in a single 10mg lyophilized vial.
A fixed formulation can support controlled analytical comparisons by maintaining the same nominal component proportions across samples.
Researchers exploring peptide classifications and receptor-related laboratory studies can review the list of research peptides for additional background information.
GLP-1 (S) / Cagri Blend 10mg Specifications
| Property | Value |
| Product name | GLP-1 (S) / Cagri Blend |
| Components | Semaglutide 5mg + Cagrilintide 5mg |
| Total per vial | 10mg |
| Blend ratio | 1:1 by weight |
| Semaglutide peptide type | Lipidated GLP-1 analogue |
| Semaglutide receptor target | GLP-1 receptor |
| Cagrilintide peptide type | Long-acting amylin analogue |
| Cagrilintide receptor targets | Amylin receptor complexes and related calcitonin-family receptors |
| Semaglutide molecular weight | Approximately 4113.6 g/mol |
| Form | Lyophilized powder |
| Purity | 99.76% |
Semaglutide – GLP-1 Receptor Agonist
Semaglutide is a synthetic, lipidated analogue of glucagon-like peptide-1, a naturally occurring peptide hormone.
Its molecular structure is modified to support prolonged biological activity compared with native GLP-1.
In research settings, Semaglutide is investigated through receptor-binding assays, molecular characterization and biochemical studies involving GLP-1 receptor signalling.
Researchers also examine its peptide structure, stability characteristics and ligand-receptor interactions in controlled experimental models.
Cagrilintide – Long-Acting Amylin Analogue
Cagrilintide is a synthetic, long-acting analogue of amylin, a peptide hormone associated with pancreatic endocrine signalling.
It is investigated for its interactions with amylin receptor complexes, which involve calcitonin receptor proteins and receptor activity-modifying proteins.
Laboratory studies examine Cagrilintide’s molecular structure, receptor-binding characteristics and signalling activity.
Its receptor profile differs from that of Semaglutide, making the two compounds relevant to comparative research involving distinct peptide-signalling pathways.
Certificate of Analysis
PCH Peptides provides batch-specific analytical documentation for its peptide research materials.
The GLP-1 (S) / Cagri Blend is listed in the PCH Peptides COA Library, where researchers can review available testing records.
The applicable Certificate of Analysis should be checked for component identity, analytical purity and batch-specific findings.
For a two-component formulation, researchers should also verify whether the analytical documentation reports separate results for Semaglutide and Cagrilintide or a combined measurement for the finished blend.
The exact purity percentage should be taken from the current batch COA rather than assumed from general product testing claims.
For more information about research material classifications and documentation, review the Research Use Only Peptides Guide.
Storage and Handling
Keep the GLP-1 (S) / Cagri Blend vial sealed until required for an authorized laboratory workflow.
Store the lyophilized material in a cold, dry environment protected from moisture, excessive heat and direct light. Follow the storage conditions specified on the product label and applicable batch documentation.
Appropriate storage and handling procedures are important for maintaining the integrity of peptide research materials during laboratory analysis.
Reconstitution Solution is available separately for suitable laboratory applications.
Researchers seeking general background information about lyophilized peptide handling can review the educational article on how peptide reconstitution works.
Related Research Materials
Laboratories investigating peptide receptor signalling and ligand-receptor interactions may also examine other compounds associated with incretin and related endocrine research pathways.
- GLP-2 (T) – A synthetic peptide associated with dual GIP and GLP-1 receptor agonism, investigated in biochemical and receptor-binding research.
- GLP-3 (R) – A synthetic peptide studied for interactions with GLP-1, GIP and glucagon receptors in multi-receptor signalling models.
Unlike the GLP-1 (S) / Cagri Blend, which contains two distinct peptide compounds, GLP-2 (T) and GLP-3 (R) are individual molecular entities with activity across multiple receptor pathways.
These materials support different approaches to comparative molecular characterization and receptor-interaction studies.
For broader educational information about peptide structures and classifications, explore the PCH Peptides research guide.
Frequently Asked Questions
What is in the GLP-1 (S) / Cagri Blend?
Each vial contains 5mg Semaglutide and 5mg Cagrilintide, providing a total of 10mg of lyophilized research material.
The two compounds are combined in a fixed 1:1 ratio by weight for laboratory research applications.
What receptors does the GLP-1 (S) / Cagri Blend target?
Semaglutide interacts with the GLP-1 receptor, while Cagrilintide interacts with amylin receptor complexes and related calcitonin-family receptor systems.
Researchers examine these distinct receptor pathways in controlled biochemical and molecular signalling studies.
Why are Semaglutide and Cagrilintide studied together?
Semaglutide and Cagrilintide have different molecular structures and receptor-interaction profiles.
Researchers investigate them together to examine the characteristics of combined peptide formulations and compare signalling activity across GLP-1 and amylin-related receptor pathways.
These studies do not establish the safety or effectiveness of this research-grade blend for human use.
What is the ratio of Semaglutide to Cagrilintide in this blend?
The formulation contains 5mg Semaglutide and 5mg Cagrilintide, giving a 1:1 ratio by weight.
The total amount of research material is 10mg per vial.
How is this blend different from GLP-2 (T) and GLP-3 (R)?
GLP-1 (S) / Cagri Blend combines two separate peptide compounds that interact with different receptor systems.
GLP-2 (T) is associated with dual GIP and GLP-1 receptor agonism within a single peptide molecule.
GLP-3 (R) is associated with triple-receptor activity involving GLP-1, GIP and glucagon receptors.
These structural and receptor-related differences make the compounds relevant to different comparative research models.
What is the molecular weight of Semaglutide?
Semaglutide has an approximate molecular weight of 4113.6 g/mol.
Because the GLP-1 (S) / Cagri Blend contains two distinct compounds, it does not have a single molecular weight representing the entire mixture.
Each component has its own molecular structure and molecular weight.
Is the GLP-1 (S) / Cagri Blend batch tested?
PCH Peptides provides a Certificate of Analysis listing for the GLP-1 (S) / Cagri Blend.
Researchers should review the applicable batch report to confirm the available identity testing, purity measurements and other analytical findings.
The documentation can be accessed through the COA Library.
How should the GLP-1 (S) / Cagri Blend be stored?
The blend should remain sealed and protected from moisture, excessive heat and direct light.
Follow the temperature and handling recommendations provided on the product label and any applicable batch-specific documentation.
Is the GLP-1 (S) / Cagri Blend intended for human use?
No. This formulation is supplied strictly for laboratory, academic and institutional research.
It is not intended for human or animal consumption, injection, therapeutic applications, diagnosis or veterinary use.
For more information about research material restrictions, read the Research Use Only Peptides Guide.
Do you provide dosage instructions for the GLP-1 (S) / Cagri Blend?
No. PCH Peptides does not provide dosage, administration or usage protocols. GLP-1 (S) / Cagri Blend is supplied exclusively for qualified research use only.
